Immunocore Holdings plc (NASDAQ:IMCR) Receives Consensus Recommendation of “Buy” from Analysts

Immunocore Holdings plc (NASDAQ:IMCRGet Rating) has been given an average recommendation of “Buy” by the nine brokerages that are presently covering the firm, MarketBeat reports. Nine analysts have rated the stock with a buy rating. The average 1-year target price among brokers that have covered the stock in the last year is $79.13.

Several research analysts have issued reports on the company. Barclays initiated coverage on Immunocore in a report on Wednesday, November 30th. They issued an “overweight” rating and a $80.00 price target on the stock. JPMorgan Chase & Co. increased their price objective on Immunocore from $60.00 to $67.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 14th. HC Wainwright increased their price objective on Immunocore from $80.00 to $90.00 and gave the stock a “buy” rating in a research note on Monday, November 21st. The Goldman Sachs Group raised Immunocore from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $33.00 to $80.00 in a research note on Friday, December 16th. Finally, Morgan Stanley increased their price target on Immunocore from $72.00 to $79.00 and gave the company an “overweight” rating in a research report on Thursday, November 10th.

Hedge Funds Weigh In On Immunocore

A number of large investors have recently made changes to their positions in the stock. RTW Investments LP boosted its holdings in shares of Immunocore by 11.4% in the third quarter. RTW Investments LP now owns 4,451,483 shares of the company’s stock worth $208,953,000 after acquiring an additional 455,329 shares during the period. Rock Springs Capital Management LP boosted its stake in Immunocore by 3.3% during the first quarter. Rock Springs Capital Management LP now owns 2,552,034 shares of the company’s stock valued at $76,306,000 after buying an additional 80,479 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Immunocore by 270.7% during the third quarter. Price T Rowe Associates Inc. MD now owns 1,163,561 shares of the company’s stock valued at $54,618,000 after buying an additional 849,662 shares during the period. First Manhattan Co. boosted its stake in Immunocore by 58.6% during the first quarter. First Manhattan Co. now owns 808,549 shares of the company’s stock valued at $24,175,000 after buying an additional 298,693 shares during the period. Finally, BlackRock Inc. lifted its stake in Immunocore by 0.7% during the third quarter. BlackRock Inc. now owns 499,432 shares of the company’s stock worth $23,444,000 after purchasing an additional 3,250 shares during the last quarter. 65.11% of the stock is owned by institutional investors.

Immunocore Stock Up 6.0 %

Shares of Immunocore stock opened at $54.54 on Wednesday. Immunocore has a one year low of $18.43 and a one year high of $69.06. The company has a debt-to-equity ratio of 0.25, a current ratio of 5.23 and a quick ratio of 5.21. The stock’s 50-day moving average is $58.84 and its 200 day moving average is $51.63. The firm has a market cap of $2.40 billion, a price-to-earnings ratio of -31.71 and a beta of 0.55.

Immunocore (NASDAQ:IMCRGet Rating) last announced its quarterly earnings results on Wednesday, November 9th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.40. The business had revenue of $48.52 million for the quarter, compared to analyst estimates of $37.73 million. Immunocore had a negative return on equity of 29.53% and a negative net margin of 59.17%. Equities research analysts anticipate that Immunocore will post -0.54 EPS for the current year.

About Immunocore

(Get Rating)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers.

Featured Stories

Analyst Recommendations for Immunocore (NASDAQ:IMCR)

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.